Tisagenlecleucel in Pediatric Patients With Acute Lymphoblastic Leukemia

  H&O  What is tisagenlecleucel? SM  Tisagenlecleucel (Kymriah, Novartis) is an engineered T-cell therapy that uses a chimeric antigen receptor (CAR) to redirect the cytotoxic machinery […]

Hem/Onc News

Osimertinib Approved for First-Line Treatment in Metastatic NSCLC On April 18, the US Food and Drug Administration (FDA) approved osimertinib (Tagrisso, AstraZeneca) for the first-line treatment […]